Hepatocellular Carcinoma
Conditions
Interventions
Study group:The treatment plan was determined according to the postoperative CTC counts
subjects with CTC counts =5/5mL were treated with oral lenvatinib (8mg/12mg qd) as adjuvant therapy for one year or end point, and those with CTC counts =5/5mL were followed up regularly.
Control group:The need for adjunctive oral lenvatinib (8mg/12mg qd) therapy for one year or end point, is determined by the clinician's clinical experience
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age > 18 years; 2. Clinical or pathologic diagnosis of HCC for liver transplantation and postoperative pathologic confirmation of HCC; 3. No extrahepatic metastasis of the tumor and no invasion of the vena cava and portal vein trunks as confirmed by preoperative imaging; 4. Subjects or their legal representatives agree to participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Perioperative death; 2. Tumor metastasis to extrahepatic organs or hilar lymph node metastasis (short axis >2 cm); 3. Tumor invasion of the vena cava, main hepatic vein, main portal vein or superior mesenteric vein; 4. Subjects with uncorrectable coagulation disorders, significant hematologic abnormalities, or significant bleeding tendencies; 5. Subjects who refuse to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 year disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of Circulating tumor cell;Recurrence rate;2 years overall survival; | — |
Countries
China
Contacts
Public ContactKunlin Xie
West China Hospital, Sichuan University
Outcome results
None listed